News

Fierce Pharma17h
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...
BioSpace18h
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support
The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...
pharmaphorum21h
FDA tightens heart tox warnings on mRNA COVID vaccines
According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a ...
FDA approves Novavax's COVID-19 vaccine with limitations
The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.
Fierce Pharma6d
Weighing approval bids from J&J, Pfizer and Roche, FDA scrutinizes data ahead of adcomm
One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...
Pfizer: Bearish Catalysts Brewing
Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...